NCT02451969View on ClinicalTrials.gov

Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly

PHASE3CompletedINTERVENTIONAL
Enrollment

1,760

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

February 28, 2017

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

investigational 23-valent PPV

The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.

BIOLOGICAL

control 23-valent PPV

The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.

Trial Locations (1)

475100

Kaifeng County Center for Disease Control and Prevention, Kaifeng

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT02451969 - Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly | Biotech Hunter | Biotech Hunter